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Objectives: The prevalence of newborn hearing disorders is 1-3 per 1000. Crucial for later 
outcome are correct diagnosis and effective treatment in the first year of life. With BERA and 
TEOAE low-risk techniques for early detection are available. Universal screening is recom-
mended but not realised in most European health care systems.  
Objective of the study was to examine the scientific evidence of newborn hearing screening, 
thus to compare cost-effectiveness of different programmes, differentiated by type of strategy 
(risk screening, universal screening, no screening).    
Methods: In an interdisciplinary health technology assessment project all relevant studies on 
newborn hearing screening were identified and data on medical outcome, costs and cost-
effectiveness extracted. A Markov model was designed to calculate cost-effectiveness ratios. 
Results: Economic data were extracted from 20 relevant publications. In the model total costs 
for screening of 100.000 newborns with a time horizon of ten years were calculated: 2.0 Mio 
.€ for universal screening (U), 1.0 Mio. € for risk screening (R) and 0.6 Mio. € for no screen-
ing (N). The costs per child detected: 13,395 € (U) respectively 6,715 € (R) and 4,125 € (N).  
Conclusions: A remarkable small number of economic publications mainly of low methodo-
logical quality was found. In our own model we found reasonable cost-effectiveness ratios 
also for universal screening. Considering the outcome advantages of higher numbers of cases 




According to calculation of the WHO world-wide approximately 350 Mio. People have hear-
ing disorders. The overall prevalence of congenital hearing disorders is 1-3 in 1000 newborns, 
the prevalence in risk groups is estimated at about 10 times higher. Risk factors are e.g. early 
child birth, infection in early pregnancy or family history of hearing disorders. 
The neurological development of hearing abilities requires an acustic stimulation in the first 
two years of life. Deficits due to absent acustic stimulation during the first years of life are 
nearly impossible to improve by later rehabilitation [Walger 2000]. Diagnosis and treatment 
as early as possible are necessary therefore for a successful and effective treatment of con-
genital peripheral hearing disorders. 
If congenital hearing disorders are detected and treated in time, most of the children are en-
abled to pass through a normal development of speech and no special education is necessary 
[Kiese-Himmel and Ohlwein 1999; Markides1986; Walger 2000]. For the detection of hear-
ing disorders with TEOAE (transient evoked oto-acustic emmissions) and BERA (brainstem 
evoked response audiometry) tests with a acceptable sensitivity and specificity are available. 
TEOAE is easier to perform, less time consuming and cheaper, but shows more false positive 
results. BERA requires more time, sometimes needs sedation of children, but is seen as gold 
standard for diagnosis of hearing disorders. Although for screening purposes a shorter version 
of BERA is discussed, most of the programmes are performed using TEOAE.  
Usual treatment of congenital hearing disorders consists of supply with hearing aid. If treat-
ment with hearing aids do not improve hearing, cochlea implants should be considered. 
 
The mean age of diagnosis of congenital hearing disorders in Germany, like in most other 
western countries, is 2-4 years of age, depending on the amount of hearing loss. Treatment is 
started in average 9 months later [Hartmann and Klinke 1998]. There is a marked discrepancy 
between these findings and the recommendation of international consensus groups.  
Recommendations of the European consensus development conference on neonatal hearing 
screening [European consensus conference 1998] are: diagnosis in first 6 months of life and 
treatment in first 12 months of life. To achieve an early diagnosis and treatment an universal 
screening for hearing disorders is recommended. But a regular screening of newborns is not 
implemented in Germany and most other health care systems. In Germany newborn hearing 
screening is only done by individual hospital or physicians’ own initiative and the tests are 
only reimbursed by sickness funds if there is a suspected hearing disorder.  
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The objectives of this interdisciplinary economic health technology assessment project were 
to compare the costs, effects and cost-effectiveness-ratios of three different strategies: 
1.  Universal screening of all hospital born newborns 
2.  Risk screening of all hospital born newborns with risk factors 
3.  Present situation in Germany without regular screening 
 
Cost-effectiveness ratios to be calculated were: 
1.  Costs per screened child 
2.  Costs per case detected (Case defined as hearing loss >25dB on better ear) 
3.  Costs per case detected in time (In time defined as in the first 6 months of life) 
 
The different tests or test combinations of BERA and TEOAE are available. The at present 
most common strategy is a so-called two-step TEOAE-strategy with a single TEOAE test in 
the first days of life and a second similar test a few days later, if in the first test no TEOAEs 
were detected. If the first or second test is negative, the children are classified as test negative, 






According to the methodological recommendation for health technology assessment projects 
in Germany [Leidl et al. 1999], cost and cost-outcome calculations based on published litera-
ture data combined with actual item costs were performed. To estimate long-time outcomes 
an additional Markov model was designed. 
 
COST CALCULATIONS 
As possibly relevant cost components were defined: 
 
Direct medical costs:  
•  Costs for implementation of screening programme 
•  Cost for screening tests 
•  Costs for organisation of screening programme 
•  Costs for tracking 
•  Costs for further diagnostic of (true and false) screening positives 
•  Treatment for detected cases of hearing disorder 
o Regular controls 
o Treatment with hearing aid (supply, controls, batteries etc.) 
o Treatment with cochlear implants (Pre-op, device, operation, rehabilitation) 
 
Direct non-medical costs: 
•  Transportation costs for diagnostic and treatment 
•  Caregiving time for brothers and sisters 
•  Additional education costs for special institutions for children with hearing disorders 
 
Indirect costs: 
•  Work time loss for parents 
•  Work time loss for grown up persons with hearing disorders 
•  Income loss due to hearing disorders 
•  Productivity loss due to premature mortality 
 
A predefined, externally reviewed literature search for publications on newborn hearing 
screening of all relevant electronic databases was performed. If costs or cost calculations were  
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mentioned in title, abstract or MESH-words, publications were included for the economic 
evaluation and full text versions scanned. “Gray literature” like conference booklets, relevant 
internet homepages or publications not listed in literature databases was scanned by hand. A 
detailed description of the literature search strategy can be obtained from the authors on re-
quest.  
Detected publications were scored according to a established standardised questionnaire 
[Leidl et al. 1999] and included respectively excluded for further evaluation. Data from in-
cluded studies were standardised to EUR of 1999 using the OECD PPPs and the German 
health sector specific inflation rates. Relevant economic parameter were modified and aggre-
gated if adequate. 
 
MARKOV MODEL 
For design and calculation of the Markov model the software DATA Treeage was used. The 
literature search was extended to publications dealing with direct or indirect costs of hearing 
disorders, costs and cost-effectiveness and long-time outcomes of children supplied with hear-
ing aids and/or cochlear implants. As the most widespread and relevant strategy a two-step 
TEOAE test strategy as described above was chosen. 
 


















Thought  to   be healthy  
but hearing disorder 
Healthy confirmed  
by diagnostic 
Thought  to   have hearing  
disorder but healthy 
Healthy without  
diagnostic 
Detected hearing  
disorder 
Not   compliant  
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For the cost calculations costs of TEOAE-tests, detection of children with risk factors, and 
costs for further diagnostic were included. Because of the lack of outcome or cost data costs 
for medical treatment and education of children as well as indirect costs could not be in-
cluded. 
“Universal screening” (U), “risk screening”(R),  and “no screening”(N) as above described 
were defined as alternative strategies.  
 
Predicted outcomes were defined as: 
1.  Number of true positively detected cases of congenital hearing disorder at 6 months 
2.  Number of “detected child months” at 6, 12 and 120 months 
3.  Costs per 100,000 screens 
 
The outcome “Number of detected child months” (2.) is described as the amount of months in 
the defined time frame of 6, 12 or 120 months in which a hearing disorder is known. For ex-
ample in a time horizon of 6 months a child with hearing disorder detected at birth is equiva-
lent to 6 detected child months. Detection with 4 months is equivalent to two detected child 
months. This outcome measure was chosen in addition to the classical outcome “Number of 
cases detected” (1.) to underline the importance of early detection.  
 
As cost-effectiveness outcomes were calculated: 
1.  Costs per case of hearing disorder additionally detected 
2.  Costs per detected child month 
 
A societal perspective, a discount rate of 5%, a cycle length of 1 month and a overall time 
horizon of 10 years were chosen for the base case. Sensitivity analyses were performed on all 
relevant parameter. All assumptions made and parameters used are shown in table 1.   
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Table 1: Relevant parameter and assumptions of Markov model. References on request from 
authors 
Parameter Baseline  (Range)  % 
Prevalence of congenital hearing disorder  0,15 (0,09-0,3) 
Prevalence of ≥ 1 risk factor  20 (10-30) 
Prevalence of hearing disorders   
  In children with risk factor 





Prevalence of risk factor in children  

















Participation in screening 
 
 







Probability of (false) suspect  






3 per year (0-5) 
Probability of ￿natural￿ detection of  
hearing disorder  
Empirical function of detection according to  




Overall 39 economic publications on newborn hearing screening were found. Because of a 
lack of transparent cost data 19 publications were excluded. For further calculations 20 publi-
cations remained: 16 journal articles, 3 health technology assessment reports [ANAES 1999; 
Davis et al. 1997; MSAC 1999] and 1 conference abstract. A series of three publications 
[Turner 1991; Turner 1992a; Turner 1992b] reporting the results of the same project was 
combined to one.  Because the HTA-reports did not present primary studies, overall 15 differ-
ent studies on newborn hearing screening with economic components were included. 
Besides the intervention costs for the screening test itself most of the studies limited the calcu-
lation to the costs for tracking and further diagnostic of hearing disorders. One study included 
the costs for implementation of the screening programme. The costs for further medical 
treatment of detected cases and special education were included only by one study. No study 
considered other direct non-medical cost or indirect costs. Also no studies with utility meas-
ures or health related quality of life were found (see also table 2).  
After adjustment to € of 1999 the studies showed a 4 to 5 time range of  costs for screening 
tests, tracking and further diagnostic. The highest single item costs with more than 500,000 € 
were calculated for long-time treatment and special education of children with hearing disor-
ders. In contrast to this importance these costs were included only by one study.  
With 7-36€ respectively 3-13€ the costs per screened child and the costs per case detected 
showed the same range of results. There was no systematic difference or trend towards a defi-
nite test-method (see also Table 2).  
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Cost per newborn  
(€ 2000) 
Costs per case 
detected (€ 2000) 
Long-time cost-
effectiveness ratio 
Friedland et al. 
1996 
BERA 26.90-100.56   
according to setting 
13411-49434  














Risk group: 1.59 
Universal: 9.93 
Risk group: 3097 
Universal: 11564 
- 
Kezirian et al. 
2001 
BERA 13.05-25.45 
according to test 
method 
5170-9575  
according to test 
method 
- 
Markowitz 1990  BERA  54.82-90.91 
according to test 
method 
3083-4712  





BERA 28.59  19768  - 
Maxon et al. 
1996 





27.84 total:  10692 
bilateral: 13699 
Savings: 4.2 Mio by 
54000 newborns/a 
over 12 years 
Messner et al. 
2001 
BERA 27.71  -  - 










BERA 47.53-187.38   
according to test 
method and setting 
6517-96404 
according to test 







according to test 
method 
34852-59902 
according to test 
method 
- 
Vohr et al. 2001  BERA  16.33-25.23 
according to test 
method 
8149-11666 
according to test 
method 
- 
Watkin 1996  TEOAE  17.83  8913  - 
Weirather et al. 
1997 





Graph 1 shows the structure of the Markov model. All children begin in the starting state 
“status unknown” and end up in one of the absorbing states “detected hearing disorder” or 
“healthy, confirmed by diagnostic”. With a certain probability children are screened. This 
probability is 1,0 in strategy U (universal screening), according to the prevalence of at least 
one risk factor 0,2 in strategy R (risk screening) and 0,0 in strategy N (no screening). A suc-
cessful tracking is assumed and further diagnostic is performed in all screening positive chil-
dren. The children with hearing disorders, who were not screened (in strategies R and N), are 
detected with a “natural” detection rate, based on an empirical function taken from the register 
of hearing disorders of the area of Munich.  
For the calculation presented here the at present most widespread screening strategy of a two-
step TEOAE-test was chosen.  According to the specific sensitivity and specificity of a two-
step TEOAE-screening some children are screening positive but healthy, some are screening 
negative with undetected hearing disorder. A small drop out either at screening or at follow up 
after positive screening test also is included in the model calculation. 
 
With the assumed prevalence of 0.15 % in a cohort of 100,000 newborns 150 cases of con-
genital hearing disorder are present. At 6 months of life with a universal screening strategy 
108 cases (72%) are detected, with a risk screening 64 (43 %), without regular screening 20 
(13 %). Out of possible 900 detected child months with an universal screening 630 months, 
with a risk screening 354 months and without screening 78 detected child months were 
achieved.  
The costs for screening 100,000 newborns using TEOAE are calculated with about 2.0 Mio. € 
for a universal screening, 1.0 Mio. € for screening of risk groups. The costs for a strategy 
without regular screening were 0.6 Mio. €. This leads to costs per newborn of 20 € (U), 10 € 
(R) respectively 6€ (N). The costs per case of congenital hearing disorder detected were 
calculated with 13,395 € (U), 6,715€ (R) and 4,125 € (N) (see also table 3).  
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Table 3: Results of the Markov model, base case, discount rate 5% (undiscounted) 






Detected child months  
at 6 months 
630 (634)  354 (356)  78 (79) 
Detected child months at  
12 months 
1298 (1361)  801 (813)  304 (309) 
Detected child months at  
120 months  
13926 (16205)  12063 (14178)  10201 (12153) 
Cases detected at 6 months (per 
100,000) 
108   64  20 
Cases detected at 120 months 
(per 100,000) 
150 150  150 
Incremental Analysis: 
Add. detected child months  
U vs. R: 44 
U vs. N: 88 
R vs. N: 44  - 
Total costs 





























Sensitivity analyses of all relevant parameters and assumptions were performed. Similar for 
all strategies the strongest influence on outcomes was seen if prevalence was varied. The 
variation of discount rate had little influence; the model was insensitive to test parameters 
(sensitivity and specificity) and loss to follow up. The costs were strongly influenced by 
variation of test costs, test parameters especially the number of false test positives, and the 
probability to be detected without screening. Prevalence and discount rate did not affect the 





As part of a German interdisciplinary health technology assessment project the economic con-
sequences of newborn hearing screening were investigated. In a detailed literature search over 
all nearly 700 publications dealing with hearing screening were found. Despite this relatively 
large number only 15 studies with own economic calculations were detected. Only one single 
study included costs of treatment and education and chose a time horizon of more than 1 year, 
which is considered as state of the art methodological standard. In general most of the eco-
nomic publications showed a relatively poor methodological quality according to international 
recommendation for economic evaluation studies of health care programmes [Gold et al. 
1996; CCOHTA 1996; Drummond et al. 1997]. The cost calculations were not transparent, 
sources for resource uses and valuation as well as the perspective of the calculation often re-
mained unclear.  
Possibly also due to the different methodological approaches the costs per screening test and 
the costs per case detected showed – although adjusted and standardised to one currency and 
one year – a wide range (four- to fivefold) without a clear tendency for a definite test method.   
The results of the published studies are insufficient to answer the policy question for the eco-
nomic consequences in a sense of costs and cost-effectiveness of different strategies for detec-
tion of congenital hearing disorders. There is a lack of convincing studies presenting results 
on a high level of evidence according to recommendations of evidence based medicine and 
the need for further research must be underlined. 
 
To estimate the costs and outcomes of newborn hearing screening a Markov model was de-
signed. Markov models in medical decision analysis are seen as explicit and quantifying ap-
proach for decisions between alternatives under uncertainty. The decision is made according 
to the trade off between medical risks, benefits and costs. As all models also Markov models 
are not able to reflect all aspects of clinical reality, but the most relevant structures and pa-
rameters are demonstrated and offered for discussion.  
The model presented here considers the aspects that, on one hand side, all cases of congenital 
hearing disorders are detected sooner or later, but on other hand side they should be diagnosed 
as early as possible. Therefore in addition to the classical outcome of screening studies “num-
ber of cases detected by screening” we included the date of detection in the outcome measure 
“detected child months”.  
On the outcome side expressed in the number of cases detected and the number of detected 
child months the model shows clear advantages for newborn hearing screening compared to  
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no regular screening. At the crucial date of 6 months without screening only 9% of the cases 
are detected, with a screening of children with one or more risk factors the detection rate is 
40%, with an universal screening about 70%. A universal screening strategy shows a higher 
rate of cases detected in time and a percentage of 40% detected with a risk screening seems 
not sufficient considering the importance of early diagnosis and treatment. Combining the 
mentioned advantages in medical outcome with still acceptable and reasonable costs a univer-
sal hearing screening is recommended.  
 
We chose a two-step TEOAE-strategy for the model calculation presented here, but the model 
could easily been adjusted for other test strategies. The advantage of a TEOAE-screening is 
the absence of risks and side effects for the screened children. There is no sedation or anaes-
thesia necessary and the few minutes time required is relatively short. The test itself is easy to 
perform and is not necessarily to be done by specially trained physicians.  A one-step 
TEOAE-strategy shows a higher rate of false positives, why usually a two-step strategy is 
preferred.  
 
The cost-effectiveness ratios are not directly comparable to those of other health care tech-
nologies. But with costs per case detected of 14,000€   an universal screening strategy seems 
to be reasonable if the lifelong benefits are taken into account. If it is assumed in a conserva-
tive calculation that half of the children benefit from earlier detection and their quality of life 
improves by 10% over 50 years, 2.5 QALYs are gained. The costs per QALY would be less 
than 10,000€.     
Because of the lack of literature data on health care resource use and the percentage of chil-
dren, who are able to visit a regular school after treatment with hearing aid or cochlea implant 
– the existing studies to cochlea implantation used a different population only of children with 
severe hearing disorders – the cost calculations are incomplete. Any savings connected to a 
better outcome because of an earlier detection and treatment were not included. If these sav-
ings as well as indirect costs e.g. estimated as the avoided loss of income due to hearing dis-
orders, would be included in the calculation, there might well be a overcompensation of 
screening costs. Further studies will have to answer these questions. Nevertheless the present 
data on medical and economic outcomes suggest a recommendation of a universal hearing 
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